Efficacy of lysophosphatidylcholine in combination with antimicrobial agents against Acinetobacter baumannii in experimental murine peritoneal sepsis and pneumonia models

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 8, 2016, Pages 4464-4470

  Parra Millan R ^a   Jimenez Mejias M E ^a   Sanchez Encinales V ^a   Ayerbe Algaba, R ^a   Gutierrez Valencia A ^a   Pachon Ibanez M E ^a   Diaz C ^b   Perez Del Palacio J ^b   Lopez Cortes L F ^a   Pachon J ^a   Smani, Y ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b Fundación MEDINA Centro de Excelencia en Investigaciovn de Medicamentos Innovadores en Andalucía   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; IMIPENEM; INTERLEUKIN 10; LYSOPHOSPHATIDYLCHOLINE; TIGECYCLINE; TUMOR NECROSIS FACTOR ALPHA; ANTIINFECTIVE AGENT; MINOCYCLINE; TUMOR NECROSIS FACTOR;

ACINETOBACTER BAUMANNII; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL CLEARANCE; BACTERIAL STRAIN; COLONY FORMING UNIT; COMBINATION CHEMOTHERAPY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL MODEL; FEMALE; LD100; LUNG; MONOTHERAPY; MORTALITY RATE; MOUSE; NONHUMAN; PERITONEAL SEPSIS; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; PHENOTYPE; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; SPLEEN; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ACINETOBACTER BAUMANNII; ANIMALS; ANTI-BACTERIAL AGENTS; COLISTIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMIPENEM; INTERLEUKIN-10; LYSOPHOSPHATIDYLCHOLINES; MICE; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; PNEUMONIA; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84979208601     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02708-15     Document Type: Article

References (39)

1. Dijkshoorn L, Nemec A, Seifert H. 2007. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Microbiol Rev 5:939-951. http://dx.doi.org/10.1038/nrmicro1789.
2. Pérez F, Endimiani A, Bonomo RA. 2008. Why are we afraid of Acinetobacter baumannii. Expert Rev Anti Infect Ther 6:269-271. http://dx.doi.org/10.1586/14787210.6.3.269.
3. Asensio A, Cantón R, Vaqué J, Calbo-Torrecillas F, Herruzo R, Arribas JL, Sáenz MC, Grupo de Trabajo EPINE. 2008. Prevalence of infection by carbapenem-resistant Acinetobacter baumannii in Spain (1999-2005). Enferm Infecc Microbiol Clin 26:199-204. http://dx.doi.org/10.1016/S0213-005X(08)72691-0.
4. Fernández-Cuenca F, Tomás-Carmona M, Caballero-Moyano F, Bou G, Martínez-Martínez L, Vila J, Pachón J, Cisneros JM, Rodríguez-Baño J, Pascual A, Grupo del Proyecto GEIH-REIPI-Ab 2010. 2013. In vitro activity of 18 antimicrobial agents against clinical isolates of Acinetobacter spp.: multicenter national study GEIH-REIPI-Ab 2010. Enferm Infecc Microbiol Clin 31:4-9.
5. Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ, Barrero-Almodóvar AE, García-Garmendia JL, Bernabeu-WittelI M, Gallego-Lara SL, Madrazo-Osuna J. 2003. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 36:1111-1118. http://dx.doi.org/10.1086/374337.
6. Markou N, Markantonis SL, Dimitrakis E, Panidis D, Boutzouka E, Karatzas S, Rafailidis P, Apostolakos H, Baltopoulos G. 2008. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, Gram negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther 30:143-151. http://dx.doi.org/10.1016/j.clinthera.2008.01.015.
7. Tang HJ, Chuang YC, Ko WC, Chen CC, Shieh JM, Chen CH, Lee NY, Chiang SR. 2012. Comparative evaluation of intratracheal colistimethate sodium, imipenem, and meropenem in BALB/c mice with carbapenem-resistant Acinetobacter baumannii pneumonia. Int J Infect Dis 16:e34-e40. http://dx.doi.org/10.1016/j.ijid.2011.09.015.
8. Pachón-Ibáñez ME, Docobo-Pérez F, López-Rojas R, Domínguez-Herrera J, Jiménez-Mejias ME, García-Curiel A, Pichardo C, Jiménez L, Pachón J. 2010. Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 54:1165-1172. http://dx.doi.org/10.1128/AAC.00367-09.
9. Mesquita RD, Carneiro AB, Bafica A, Gazos-Lopes F, Takiya CM, Souto-Padron T, Vieira DP, Ferreira-Pereira A, Almeida IC, Figueiredo RT, Porto BN, Bozza MT, Graca-Souza AV, Lopes AH, Atella GC, Silva-Neto MA. 2008. Trypanosoma cruzi infection is enhanced by vector saliva through immunosuppressant mechanisms mediated by lysophosphatidylcholine. Infect Immun 76:5543-5552. http://dx.doi.org/10.1128/IAI.00683-08.
10. Quinn MT, Parthasarathy S, Steinberg D. 1988. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci U S A 85:2805-2809. http://dx.doi.org/10.1073/pnas.85.8.2805.
11. Sakai M, Miyazaki A, Hakamata H, Sasaki T, Yui S, Yamazaki M, Shichiri M, Horiuchi S. 1994. Lysophosphatidylcholine plays an essential role in the mitogenic effect of oxidized low density lipoprotein on murine macrophages. J Biol Chem 269:31430-31435.
12. Lauber K, Bohn E, Krober SM, Xiao YJ, Blumenthal SG, Lindemann RK, Marini P, Wiedig C, Zobywalski A, Baksh S, Xu Y, Autenrieth IB, Schulze-Osthoff K, Belka C, Stuhler G, Wesselborg S. 2003. Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell 113:717-730. http://dx.doi.org/10.1016/S0092-8674(03)00422-7.
13. Yan JJ, Jung JS, Lee JE, Lee J, Huh SO, Kim HS, Jung KC, Cho JY, Nam JS, Suh HW, Kim YH, Song DK. 2004. Therapeutic effects of lysophosphatidylcholine in experimental sepsis. Nat Med 10:161-167. http://dx.doi.org/10.1038/nm989.
14. Smani Y, Domínguez-Herrera J, Ibáñez-Martínez J, Pachón J. 2015. Therapeutic efficacy of lysophosphatidylcholine in severe infections caused by Acinetobacter baumannii. Antimicrob Agents Chemother 59: 3920-3924. http://dx.doi.org/10.1128/AAC.04986-14.
15. Baumann P, Doudoroff M, Stanier RY. 1968. A study of the Moraxella group. II. Oxidative-negative species (genus Acinetobacter). J Bacteriol 95:1520-1541.
16. Clinical and Laboratory Standards Institute. 2014. Performance standards for antimicrobial susceptibility testing: 24th informational supplement. M100-S24. CLSI, Wayne, PA.
17. Smani Y, López-Rojas R, Domínguez-Herrera J, Docobo-Pérez F, Marti S, Vila J, Pachon J. 2012. In vitro and in vivo reduced fitness and virulence in ciprofloxacin-resistant Acinetobacter baumannii. Clin Microbiol Infect 18:E1-E4. http://dx.doi.org/10.1111/j.1469-0691.2011.03695.x.
18. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.
19. Gobin O, Lemaître F, Marchand S, Couet W, Olivier JC. 2010. Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chromatography-tandem mass spectrometry. Antimicrob Agents Chemother 54:1941-1948. http://dx.doi.org/10.1128/AAC.01367-09.
20. Ji AJ, Saunders JP, Amorusi P, Wadgaonkar ND, O'Leary K, Leal M, Dukart G, Marshall B, Fluhler EN. 2008. A sensitive human bone assay for quantitation of tigecycline using LC/MS/MS. J Pharm Biomed Anal 48:866-875. http://dx.doi.org/10.1016/j.jpba.2008.06.020.
21. Sakka SG, Glauner AK, Bulitta JB, Kinzig-Schippers M, Pfister W, Drusano GL, Sörgel F. 2007. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenemcilastatin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother 51:3304-3310. http://dx.doi.org/10.1128/AAC.01318-06.
22. Usansky JL, Desai A, Tang-Liu D. 2012, accession date. PK functions for Microsoft Excel. Department of Pharmacokinetics and Drug Metabolism, Allergan, Irvine, CA.
23. Dudhani RV, Turnidge JD, Nation RL, Li J. 2010. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J Antimicrob Chemother 65:1984-1990. http://dx.doi.org/10.1093/jac/dkq226.
24. Docobo-Pérez F, Nordmann P, Domínguez-Herrera J, López-Rojas R, Smani Y, Poirel L, Pachón J. 2012. Efficacies of colistin and tigecycline in mice with experimental pneumonia due to NDM-1-producing strains of Klebsiella pneumoniae and Escherichia coli. Int J Antimicrob Agents 39: 251-254. http://dx.doi.org/10.1016/j.ijantimicag.2011.10.012.
25. Pichardo C, Pachón-Ibáñez ME, Docobo-Pérez F, López-Rojas R, Jiménez-Mejías ME, Garcia-Curiel A, Pachón J. 2010. Efficacy of tigecycline vs. imipenem in the treatment of experimental Acinetobacter baumannii murine pneumonia. Eur J Clin Microbiol Infect Dis 29:527-531. http://dx.doi.org/10.1007/s10096-010-0890-6.
26. Smani Y, Dominguez-Herrera J, Pachón J. 2013. Association of the outer membrane protein Omp33 with fitness and virulence of Acinetobacter baumannii. J Infect Dis 208:1561-1570. http://dx.doi.org/10.1093/infdis/jit386.
27. Vila J, Pachón J. 2011. Acinetobacter baumannii resistant to everything: what should we do? Clin Microbiol Infect 17:955-956. http://dx.doi.org/10.1111/j.1469-0691.2011.03566.x.
28. Sun Y, Cai Y, Liu X, Bai N, Liang B, Wang R. 2013. The emergence of clinical resistance to tigecycline. Int J Antimicrob Agents 41:110-116. http://dx.doi.org/10.1016/j.ijantimicag.2012.09.005.
29. Villar M, Cano ME, Gato E, Garnacho-Montero J, Miguel Cisneros J, Ruíz de Alegría C, Fernández-Cuenca F, Martínez-Martínez L, Vila J, Pascual A, Tomás M, Bou G, Rodríguez-Baño J, GEIH/GEMARA/REIPI-Ab2010 Group. 2014. Epidemiologic and clinical impact of Acinetobacter baumannii colonization and infection: a reappraisal. Medicine 93:202-210. http://dx.doi.org/10.1097/MD.0000000000000036.
30. Smani Y, Domínguez-Herrera J, Pachón J. 2011. Rifampin protects human lung epithelial cells against cytotoxicity induced by clinical multi and pandrug-resistant Acinetobacter baumannii. J Infect Dis 203:1110-1119. http://dx.doi.org/10.1093/infdis/jiq159.
31. Smani Y, Docobo-Pérez F, McConnell MJ, Pachón J. 2011. Acinetobacter baumannii-induced lung cell death: role of inflammation, oxidative stress and cytosolic calcium. Microb Pathog 50:224-232. http://dx.doi.org/10.1016/j.micpath.2011.01.008.
32. Kim CH, Jeong YJ, Lee J, Jeon SJ, Park SR, Kang MJ, Park JH, Park JH. 2013. Essential role of Toll-like receptor 4 in Acinetobacter baumannii-induced immune responses in immune cells. Microb Pathog 54:20-25. http://dx.doi.org/10.1016/j.micpath.2012.08.008.
33. Grguric-Smith LM, Lee HH, Gandhi JA, Brennan MB, DeLeon-Rodriguez CM, Coelho C, Han G, Martinez LR. 2015. Neutropenia exacerbates infection by Acinetobacter baumannii clinical isolates in a murine wound model. Front Microbiol 6:1134. http://dx.doi.org/10.3389/fmicb.2015.01134.
34. Breslow JM, Meissler JJ, Jr, Hartzell RR, Spence PB, Truant A, Gaughan J, Eisenstein TK. 2011. Innate immune responses to systemic Acinetobacter baumannii infection in mice: neutrophils, but not interleukin-17, mediate host resistance. Infect Immun 79:3317-3327. http://dx.doi.org/10.1128/IAI.00069-11.
35. Qiu H, KuoLee R, Harris G, Chen W. 2009. High susceptibility to respiratory Acinetobacter baumannii infection in A/J mice is associated with a delay in early pulmonary recruitment of neutrophils. Microbes Infect 11:946-955. http://dx.doi.org/10.1016/j.micinf.2009.06.003.
36. Lin L, Tan B, Pantapalangkoor P, Ho T, Baquir B, Tomaras A, Montgomery JI, Reilly U, Barbacci EG, Hujer K, Bonomo RA, Fernandez L, Hancock RE, Adams MD, French SW, Buslon VS, Spellberg B. 2012. Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis. mBio 3:e00312-12. http://dx.doi.org/10.1128/mBio.00312-12.
37. Prabhakara R, Harro JM, Leid JG, Keegan AD, Prior ML, Shirtliff ME. 2011. Suppression of the inflammatory immune response prevents the development of chronic biofilm infection due to methicillin-resistant Staphylococcus aureus. Infect Immun 79:5010-5018. http://dx.doi.org/10.1128/IAI.05571-11.
38. Cheng AC, Stephens DP, Currie BJ. 2007. Granulocyte-colony stimulating factor (G-CSF) as an adjunct to antibiotics in the treatment of pneumonia in adults. Cochrane Database Syst Rev 2:CD004400.
39. Blum CA, Nigro N, Briel M, Schuetz P, Ullmer E, Suter-Widmer I, Winzeler B, Bingisser R, Elsaesser H, Drozdov D, Arici B, Urwyler SA, Refardt J, Tarr P, Wirz S, Thomann R, Baumgartner C, Duplain H, Burki D, Zimmerli W, Rodondi N, Mueller B, Christ-Crain M. 2015. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 385:1511-1518. http://dx.doi.org/10.1016/S0140-6736(14)62447-8.